Home - Actinogen

View recent announcement >

We are pleased to provide an update on the ongoing progress with the clinical development of Xanamem, as well as advise of an upcoming presentation at the Alzheimer’s Association International Conference (AAIC) in Los Angeles, USA.

Listen to interview

Dr Bill Ketelbey, CEO Actinogen Medical provides an update on the Xanamem Clinical Development Program. “…We are now seeing results from the nine studies that are running in parallel to XanADu. These studies are going to help interpret the XanADu results and will develop a comprehensive database for Xanamem itself that will allow us in the next few months to develop a good solid strategic plan for the future development of Xanamem…” said Dr Bill Ketelbey

View video >

Dr Bill Ketelbey, CEO, provides an overview of Actinogen, their lead compound Xanamem that inhibits excess cortisol production in the brain and discusses how chronically raised cortisol is associated with cognitive impairment and the development and progression of Alzheimer’s disease. Find out the excellent progress made, what the next steps are and the way forward in a number of new indications.

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive impairment associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.

Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.

Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.

Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.

"Given the growing number of people with Alzheimer's and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer's patients, and their carers and families worldwide."

DR BILL KETELBEY, CEO & MANAGING DIRECTOR

Board of Directors

DR. Geoff Brooke

Chairman